Nesiritide: a new drug for the treatment of decompensated heart failure.
Nesiritide, a recombinant human B-type natriuretic peptide, is the first in a new drug class for the treatment of decompensated heart failure. The drug binds to receptors in the vasculature, kidney, adrenal gland, and brain, and overcomes resistance to endogenous BNP present in patients with CHF. Nesiritide administration leads to a rapid and balanced vasodilatory effect, which results in a significant decrease in right and left ventricular filling pressures and systemic vascular resistance and at the same time in an increase in stroke volume and cardiac output without a change in heart rate. These early hemodynamic changes result in a rapid improvement in symptoms of heart failure. In addition, nesiritide lowers aldosterone, catecholamines, and endothelin-1 levels and its effect on the kidney leads to an increased natriuresis and diuresis without effect on serum potassium or renal function. Prior to its approval for clinical use, nesiritide was studied in 10 different clinical trials involving 941 patients with moderate and severe CHF, including elderly patients, patients with both systolic and diastolic dysfunction, and patients with arrhythmias, renal insufficiency, and acute ischemic syndrome. In comparative studies with available vasoactive therapies frequently used for treatment of patients with decompensated heart failure, nesiritide was proven comparable in efficacy to inotropic drugs such as dobutamine, but superior in safety. In a recent study, nesiritide was found to be more effective and better tolerated than the vasodilator, nitroglycerin. The most common side effects expected with the use of nesiritide are headaches and decrease in blood pressure. At the recommended dose of nesiritide, headache was reported during the first 24 hours of treatment in 8% of patients and symptomatic hypotension in 4% of patients, compared to 20% and 5% in nitroglycerin-treated patients.
Elkayam
Uri
U
Heart Failure Program-Division of Cardiology, University of Southern California School of Medicine, 1200 N State Street, Los Angeles, CA 90033, USA.
Akhter
Mohammed Waseem
MW
Tummala
Priya
P
Khan
Salman
S
Singh
Harpreet
H
D000818:Animals; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D045283:Natriuretic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain
D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain